



The Tisch Cancer Institute

Thank you for everyone's patience and quick responses to our requests to slow down clinical research activities over this last week. It has been a difficult time and we are all concerned that withholding options for novel therapies on clinical trials will have a negative impact on our patients. We appreciate everyone's willingness to be flexible with their clinical trial visits for patients on study and for being selective in considering which studies are really necessary to remain open for accrual. We know that resources to support even standard of care treatments will be stretched thin over the next few weeks and the risks of being in the clinic for our patients are significant. We will continue to follow the directives that come from the Dean's office including the two that were sent today. Our current guidelines (attached) remain appropriate in the context of the two additional guidances that came out today.

To summarize our efforts to date:

- We have compiled the list of clinical trials that were sent to us by each team that we have submitted to PPHS for approval to remain open to accruals. As per the Dean's Guidance #3, we are trying to slow down new accruals unless it is deemed absolutely necessary, in which case, please submit the justification to Lisa Gaynes (lisa.gaynes@mssm.edu) and we will review for allocation of resources.
- We will be submitting the weekly clinical trial in-person visits to PPHS for approval on Fridays. Please try to minimize in-person clinic visits to only essential visits (see attached).

We hope to be able to balance the effects of the COVID-19 crisis and the need to provide optimal treatment for our patients. This is a link to the TCI guidances that we have sent out, you can download this on your phone: <https://rtc.careteamapp.com/home>

I apologize if you received this email more than once, I have been asked to include several distribution lists.

Thank you again,

Karyn A. Goodman, M.D., M.S.
Professor and Vice Chair of Clinical Research
Department of Radiation Oncology
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute

Ramon Parsons, M.D., Ph.D.
Icahn Scholar
Ward-Coleman Chair in Cancer Research
Director, Tisch Cancer Institute,
Icahn School of Medicine at Mount Sinai
Director, Mount Sinai Cancer, Mount Sinai Health System
Professor and Chairman, Department of Oncological Sciences

